Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma

Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA resection, particularly postoperative recurrence, remain unclear. We pathologically reevaluated 1362 lung adenocarcinoma resections performed a...

Full description

Saved in:
Bibliographic Details
Published inThe Annals of thoracic surgery Vol. 112; no. 4; pp. 1118 - 1126
Main Authors Matsui, Takuya, Sakakura, Noriaki, Koyama, Shin, Nakanishi, Keita, Sasaki, Eiichi, Kato, Seiichi, Hosoda, Waki, Murakami, Yoshiko, Kuroda, Hiroaki, Yatabe, Yasushi
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.10.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA resection, particularly postoperative recurrence, remain unclear. We pathologically reevaluated 1362 lung adenocarcinoma resections performed at our institution, categorizing cases into the IMA group (72 cases) and non-IMA group (1290 cases). The IMA group was further classified into pneumonia and nodular types based on preoperative computed tomography. Overall, the IMA group had lower carcinoembryonic antigen levels (3 vs 8 ng/mL; P < .01), fewer lymph node metastasis (4% vs 24%; P < .01), and more KRAS mutations (56% vs 7%; P < .01) than the non-IMA group. Although postoperative recurrence rates did not differ between both groups (32% vs 27%; P = 0.35), lung recurrence occurred more frequently in the IMA group (83% vs 17%; P < .01). Propensity score-matched pair analysis showed that the IMA group had fewer lymph node metastasis (3% vs 35%; P < .01), more KRAS mutations (56% vs 9%; P < .01), and higher intrapulmonary recurrence rate (84% vs 31%; P < .01) than the non-IMA group. The 5-year overall survival rates did not differ between both groups (74% vs 81%; P = 0.26). However, among patients with intrapulmonary recurrence, those in the IMA group had significantly worse prognosis than those in the non-IMA group (35% vs 77%; P < .01). Intrapulmonary recurrence, which induced significantly worse prognosis, was more likely to occur in the IMA than non-IMA group. [Display omitted]
AbstractList Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA resection, particularly postoperative recurrence, remain unclear. We pathologically reevaluated 1362 lung adenocarcinoma resections performed at our institution, categorizing cases into the IMA group (72 cases) and non-IMA group (1290 cases). The IMA group was further classified into pneumonia and nodular types based on preoperative computed tomography. Overall, the IMA group had lower carcinoembryonic antigen levels (3 vs 8 ng/mL; P < .01), fewer lymph node metastasis (4% vs 24%; P < .01), and more KRAS mutations (56% vs 7%; P < .01) than the non-IMA group. Although postoperative recurrence rates did not differ between both groups (32% vs 27%; P = 0.35), lung recurrence occurred more frequently in the IMA group (83% vs 17%; P < .01). Propensity score-matched pair analysis showed that the IMA group had fewer lymph node metastasis (3% vs 35%; P < .01), more KRAS mutations (56% vs 9%; P < .01), and higher intrapulmonary recurrence rate (84% vs 31%; P < .01) than the non-IMA group. The 5-year overall survival rates did not differ between both groups (74% vs 81%; P = 0.26). However, among patients with intrapulmonary recurrence, those in the IMA group had significantly worse prognosis than those in the non-IMA group (35% vs 77%; P < .01). Intrapulmonary recurrence, which induced significantly worse prognosis, was more likely to occur in the IMA than non-IMA group. [Display omitted]
Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA resection, particularly postoperative recurrence, remain unclear.BACKGROUNDInvasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA resection, particularly postoperative recurrence, remain unclear.We pathologically reevaluated 1362 lung adenocarcinoma resections performed at our institution, categorizing cases into the IMA group (72 cases) and non-IMA group (1290 cases). The IMA group was further classified into pneumonia and nodular types based on preoperative computed tomography.METHODSWe pathologically reevaluated 1362 lung adenocarcinoma resections performed at our institution, categorizing cases into the IMA group (72 cases) and non-IMA group (1290 cases). The IMA group was further classified into pneumonia and nodular types based on preoperative computed tomography.Overall, the IMA group had lower carcinoembryonic antigen levels (3 vs 8 ng/mL; P < .01), fewer lymph node metastasis (4% vs 24%; P < .01), and more KRAS mutations (56% vs 7%; P < .01) than the non-IMA group. Although postoperative recurrence rates did not differ between both groups (32% vs 27%; P = 0.35), lung recurrence occurred more frequently in the IMA group (83% vs 17%; P < .01). Propensity score-matched pair analysis showed that the IMA group had fewer lymph node metastasis (3% vs 35%; P < .01), more KRAS mutations (56% vs 9%; P < .01), and higher intrapulmonary recurrence rate (84% vs 31%; P < .01) than the non-IMA group. The 5-year overall survival rates did not differ between both groups (74% vs 81%; P = 0.26). However, among patients with intrapulmonary recurrence, those in the IMA group had significantly worse prognosis than those in the non-IMA group (35% vs 77%; P < .01).RESULTSOverall, the IMA group had lower carcinoembryonic antigen levels (3 vs 8 ng/mL; P < .01), fewer lymph node metastasis (4% vs 24%; P < .01), and more KRAS mutations (56% vs 7%; P < .01) than the non-IMA group. Although postoperative recurrence rates did not differ between both groups (32% vs 27%; P = 0.35), lung recurrence occurred more frequently in the IMA group (83% vs 17%; P < .01). Propensity score-matched pair analysis showed that the IMA group had fewer lymph node metastasis (3% vs 35%; P < .01), more KRAS mutations (56% vs 9%; P < .01), and higher intrapulmonary recurrence rate (84% vs 31%; P < .01) than the non-IMA group. The 5-year overall survival rates did not differ between both groups (74% vs 81%; P = 0.26). However, among patients with intrapulmonary recurrence, those in the IMA group had significantly worse prognosis than those in the non-IMA group (35% vs 77%; P < .01).Intrapulmonary recurrence, which induced significantly worse prognosis, was more likely to occur in the IMA than non-IMA group.CONCLUSIONSIntrapulmonary recurrence, which induced significantly worse prognosis, was more likely to occur in the IMA than non-IMA group.
Author Sakakura, Noriaki
Hosoda, Waki
Murakami, Yoshiko
Sasaki, Eiichi
Yatabe, Yasushi
Kato, Seiichi
Kuroda, Hiroaki
Koyama, Shin
Nakanishi, Keita
Matsui, Takuya
Author_xml – sequence: 1
  givenname: Takuya
  surname: Matsui
  fullname: Matsui, Takuya
  organization: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan
– sequence: 2
  givenname: Noriaki
  surname: Sakakura
  fullname: Sakakura, Noriaki
  email: nsakakura@aichi-cc.jp
  organization: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan
– sequence: 3
  givenname: Shin
  surname: Koyama
  fullname: Koyama, Shin
  organization: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan
– sequence: 4
  givenname: Keita
  surname: Nakanishi
  fullname: Nakanishi, Keita
  organization: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan
– sequence: 5
  givenname: Eiichi
  surname: Sasaki
  fullname: Sasaki, Eiichi
  organization: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan
– sequence: 6
  givenname: Seiichi
  surname: Kato
  fullname: Kato, Seiichi
  organization: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan
– sequence: 7
  givenname: Waki
  surname: Hosoda
  fullname: Hosoda, Waki
  organization: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan
– sequence: 8
  givenname: Yoshiko
  surname: Murakami
  fullname: Murakami, Yoshiko
  organization: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan
– sequence: 9
  givenname: Hiroaki
  surname: Kuroda
  fullname: Kuroda, Hiroaki
  organization: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan
– sequence: 10
  givenname: Yasushi
  surname: Yatabe
  fullname: Yatabe, Yasushi
  organization: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan
BookMark eNqNkc9P2zAUgK0JpJWy_8HHXZLZTuLGFzSoBkPqxmHjiuU-v4BLYne2U8R_v1SdmMSpJ7-fn54-n5ETHzwSQjkrOePyy6Y0-SlEA2mMpWCClUyVrBYfyIw3jSikaNQJmTHGqqJWi-YjOUtpM6Vias_IwzIMWxNdCp6Gjv4a46MD09O7MUMYMNErzC-Int76nUluh_THCM6HMVHjLf0ZfPFWWI3-kV5a9AFM3NcGc05OO9Mn_PTvnZP762-_l9-L1d3N7fJyVUDD21xIKzsUtjVyiuq1BJBrY1nHeCUXqrN1ZVUFCwGtRega3qgWOmGqdQXGKsGrOfl84G5j-DNiynpwCbDvjcfpNC1q2dQ1Z62aRtvDKMSQUsROb6MbTHzVnOm9Ur3R_5XqvVLNlJ6UTqsX71bBZZNd8Dka1x8DuDoAcHKxcxh1Aoce0LqIkLUN7hjI13cQ6J3f_9ozvh6H-AvDg7R1
CitedBy_id crossref_primary_10_1007_s12262_023_03688_1
crossref_primary_10_1007_s11748_024_02103_0
crossref_primary_10_2147_IJGM_S479978
crossref_primary_10_1016_j_chpulm_2024_100104
crossref_primary_10_1186_s12957_024_03326_4
crossref_primary_10_1186_s12885_024_13068_x
crossref_primary_10_1148_rg_230136
crossref_primary_10_1016_j_heliyon_2024_e30209
crossref_primary_10_1186_s12885_024_12714_8
crossref_primary_10_2214_AJR_22_28139
crossref_primary_10_1016_j_ejso_2024_108053
crossref_primary_10_1111_1759_7714_14687
crossref_primary_10_1080_14796694_2024_2405457
crossref_primary_10_1164_rccm_202301_0124IM
crossref_primary_10_1038_s41598_024_69138_4
crossref_primary_10_1016_j_cllc_2024_05_004
crossref_primary_10_1007_s00432_022_04022_0
crossref_primary_10_1097_PAS_0000000000001938
crossref_primary_10_1177_15330338241308307
crossref_primary_10_1245_s10434_023_14193_w
crossref_primary_10_1016_j_crad_2024_08_008
crossref_primary_10_1002_ccr3_7707
crossref_primary_10_1016_j_lungcan_2023_107348
crossref_primary_10_1016_j_trre_2023_100772
crossref_primary_10_1016_j_jtho_2024_11_016
crossref_primary_10_4103_jcrt_jcrt_2334_21
crossref_primary_10_1245_s10434_024_15541_0
crossref_primary_10_3390_ijms25158413
Cites_doi 10.1016/j.lungcan.2013.06.012
10.1067/mtc.2001.110190
10.1097/JTO.0b013e318221f701
10.1016/j.lungcan.2016.11.004
10.1016/j.jtho.2016.03.011
10.1097/JTO.0b013e318206a221
10.1200/JCO.2012.46.9270
10.1002/cncr.26010
10.1038/modpathol.2010.232
10.1097/PAS.0b013e31826be303
10.1097/JTO.0b013e3182769aa8
10.1016/j.humpath.2013.05.026
10.1200/JCO.2005.19.240
10.1097/JTO.0000000000000630
10.1097/JTO.0000000000000579
10.1378/chest.123.6.1868
10.1097/PAS.0000000000000246
ContentType Journal Article
Copyright 2021 The Society of Thoracic Surgeons
Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2021 The Society of Thoracic Surgeons
– notice: Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
7X8
DOI 10.1016/j.athoracsur.2020.09.042
DatabaseName CrossRef
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
EISSN 1552-6259
EndPage 1126
ExternalDocumentID 10_1016_j_athoracsur_2020_09_042
S0003497520320014
GroupedDBID ---
--K
.1-
.55
.FO
.GJ
0R~
1B1
1P~
1~5
23M
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
6J9
7-5
71M
AAEDT
AAEDW
AAEJM
AALRI
AAQFI
AAQQT
AAQXK
AAXUO
ABJNI
ABLJU
ABMAC
ABOCM
ABWVN
ACGFO
ACGFS
ACIUM
ACRPL
ACVFH
ADBBV
ADCNI
ADMUD
ADNMO
AENEX
AEUPX
AEVXI
AFFNX
AFPUW
AFRHN
AFTJW
AGCQF
AGHFR
AGQPQ
AI.
AIGII
AITUG
AJJEV
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
ASPBG
AVWKF
AZFZN
BAWUL
BELOY
C5W
CS3
DIK
E3Z
EBS
EFJIC
EFKBS
EJD
F5P
FDB
FEDTE
FGOYB
GBLVA
GX1
HVGLF
HZ~
IH2
IHE
J1W
J5H
K-O
KOM
L7B
M41
MO0
N9A
NQ-
O9-
OA-
OK1
OL.
OVD
P2P
P6G
PC.
R2-
ROL
RPZ
SES
SSZ
TEORI
TR2
UDS
UNMZH
UV1
VH1
W8F
X7M
XH2
XPP
Z5R
ZGI
ZXP
AAIAV
ACRZS
ADPAM
AFCTW
AGZHU
AHPSJ
ALXNB
RIG
ZA5
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c518t-6d6fe2d8a66d64b6cc6bad0f013679fd43d93c72c8decf51598cf2a3b3cad9213
ISSN 0003-4975
1552-6259
IngestDate Fri Jul 11 05:00:09 EDT 2025
Thu Apr 24 22:53:12 EDT 2025
Tue Jul 01 03:18:44 EDT 2025
Fri Feb 23 02:42:55 EST 2024
Tue Aug 26 16:47:53 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords ATS
DFS
CT
IASLC
BAC
OS
CI
ERS
IMA
EGFR
WHO
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c518t-6d6fe2d8a66d64b6cc6bad0f013679fd43d93c72c8decf51598cf2a3b3cad9213
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PQID 2465441089
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_2465441089
crossref_primary_10_1016_j_athoracsur_2020_09_042
crossref_citationtrail_10_1016_j_athoracsur_2020_09_042
elsevier_sciencedirect_doi_10_1016_j_athoracsur_2020_09_042
elsevier_clinicalkey_doi_10_1016_j_athoracsur_2020_09_042
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate October 2021
2021-10-00
20211001
PublicationDateYYYYMMDD 2021-10-01
PublicationDate_xml – month: 10
  year: 2021
  text: October 2021
PublicationDecade 2020
PublicationTitle The Annals of thoracic surgery
PublicationYear 2021
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Yoshizawa, Motoi, Riely (bib7) 2011; 24
Tsuta, Kawago, Inoue (bib5) 2013; 81
Russell, Wainer, Wright (bib6) 2011; 6
Cha, Kim, Lee (bib17) 2016; 102
Travis, Brambilla, Nicholson (bib2) 2015; 10
Yoshizawa, Sumiyoshi, Sonobe (bib13) 2013; 8
Ichinokawa, Ishii, Nagai (bib16) 2013; 44
Travis, Brambilla, Gregory (bib3) 2013; 31
Miller, Hirsch, Johnson (bib12) 2005; 23
Sugano, Nagasaka, Sasaki (bib4) 2013; 37
Lee, Cha, Lee (bib9) 2016; 11
Travis, Brambilla, Noguchi (bib1) 2011; 6
Breathnach, Kwiatkowski, Finkelstein (bib10) 2001; 121
Kadota, Yeh, D’ Angelo (bib14) 2014; 38
Kakegawa, Shimizu, Sugano (bib15) 2011; 117
Shim, Mari-Kenudson, Zheng (bib8) 2015; 10
Wislez, Massiani, Milleron (bib11) 2003; 123
Ichinokawa (10.1016/j.athoracsur.2020.09.042_bib16) 2013; 44
Shim (10.1016/j.athoracsur.2020.09.042_bib8) 2015; 10
Miller (10.1016/j.athoracsur.2020.09.042_bib12) 2005; 23
Kadota (10.1016/j.athoracsur.2020.09.042_bib14) 2014; 38
Travis (10.1016/j.athoracsur.2020.09.042_bib2) 2015; 10
Russell (10.1016/j.athoracsur.2020.09.042_bib6) 2011; 6
Tsuta (10.1016/j.athoracsur.2020.09.042_bib5) 2013; 81
Yoshizawa (10.1016/j.athoracsur.2020.09.042_bib7) 2011; 24
Wislez (10.1016/j.athoracsur.2020.09.042_bib11) 2003; 123
Lee (10.1016/j.athoracsur.2020.09.042_bib9) 2016; 11
Sugano (10.1016/j.athoracsur.2020.09.042_bib4) 2013; 37
Breathnach (10.1016/j.athoracsur.2020.09.042_bib10) 2001; 121
Kakegawa (10.1016/j.athoracsur.2020.09.042_bib15) 2011; 117
Travis (10.1016/j.athoracsur.2020.09.042_bib1) 2011; 6
Yoshizawa (10.1016/j.athoracsur.2020.09.042_bib13) 2013; 8
Travis (10.1016/j.athoracsur.2020.09.042_bib3) 2013; 31
Cha (10.1016/j.athoracsur.2020.09.042_bib17) 2016; 102
References_xml – volume: 6
  start-page: 1496
  year: 2011
  end-page: 1504
  ident: bib6
  article-title: Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification
  publication-title: J Thorac Oncol
– volume: 81
  start-page: 371
  year: 2013
  end-page: 376
  ident: bib5
  article-title: The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations
  publication-title: Lung Cancer
– volume: 6
  start-page: 244
  year: 2011
  end-page: 285
  ident: bib1
  article-title: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma
  publication-title: J Thorac Oncol
– volume: 123
  start-page: 1868
  year: 2003
  end-page: 1877
  ident: bib11
  article-title: Clinical characteristics of pneumonic-type adenocarcinoma of the lung
  publication-title: Chest
– volume: 102
  start-page: 82
  year: 2016
  end-page: 88
  ident: bib17
  article-title: Clinical course of stage IV invasive mucinous adenocarcinoma of the lung
  publication-title: Lung Cancer
– volume: 37
  start-page: 211
  year: 2013
  end-page: 218
  ident: bib4
  article-title: HNF4α as a marker for invasive mucinous adenocarcinoma of the lung
  publication-title: Am J Surg Pathol
– volume: 10
  start-page: 1156
  year: 2015
  end-page: 1162
  ident: bib8
  article-title: Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung
  publication-title: J Thorac Oncol
– volume: 23
  start-page: 3288
  year: 2005
  end-page: 3293
  ident: bib12
  article-title: Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities
  publication-title: J Clin Oncol
– volume: 121
  start-page: 42
  year: 2001
  end-page: 47
  ident: bib10
  article-title: Bronchioloalveolar carcinoma of the lung: recurrence and survival in patients with stage I disease
  publication-title: J Thorac Cardiovasc Surg
– volume: 8
  start-page: 52
  year: 2013
  end-page: 61
  ident: bib13
  article-title: Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with
  publication-title: J Thorac Oncol
– volume: 24
  start-page: 653
  year: 2011
  end-page: 664
  ident: bib7
  article-title: Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases
  publication-title: Mod Pathol
– volume: 31
  start-page: 992
  year: 2013
  end-page: 1001
  ident: bib3
  article-title: New pathologic classification of lung cancer: relevance for clinical practice and clinical trials
  publication-title: J Clin Oncol
– volume: 11
  start-page: 1064
  year: 2016
  end-page: 1073
  ident: bib9
  article-title: Prognosis in resected invasive mucinous adenocarcinomas of the lung: related factors and comparison with resected nonmucinous adenocarcinomas
  publication-title: J Thorac Oncol
– volume: 117
  start-page: 4257
  year: 2011
  end-page: 4266
  ident: bib15
  article-title: Clinicopathological features of lung adenocarcinoma with
  publication-title: Cancer
– volume: 44
  start-page: 2636
  year: 2013
  end-page: 2642
  ident: bib16
  article-title: Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with
  publication-title: Hum Pathol
– volume: 38
  start-page: 1118
  year: 2014
  end-page: 1127
  ident: bib14
  article-title: Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with
  publication-title: Am J Surg Pathol
– volume: 10
  start-page: 1243
  year: 2015
  end-page: 1260
  ident: bib2
  article-title: The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification
  publication-title: J Thorac Oncol
– volume: 81
  start-page: 371
  year: 2013
  ident: 10.1016/j.athoracsur.2020.09.042_bib5
  article-title: The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2013.06.012
– volume: 121
  start-page: 42
  year: 2001
  ident: 10.1016/j.athoracsur.2020.09.042_bib10
  article-title: Bronchioloalveolar carcinoma of the lung: recurrence and survival in patients with stage I disease
  publication-title: J Thorac Cardiovasc Surg
  doi: 10.1067/mtc.2001.110190
– volume: 6
  start-page: 1496
  year: 2011
  ident: 10.1016/j.athoracsur.2020.09.042_bib6
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e318221f701
– volume: 102
  start-page: 82
  year: 2016
  ident: 10.1016/j.athoracsur.2020.09.042_bib17
  article-title: Clinical course of stage IV invasive mucinous adenocarcinoma of the lung
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2016.11.004
– volume: 11
  start-page: 1064
  year: 2016
  ident: 10.1016/j.athoracsur.2020.09.042_bib9
  article-title: Prognosis in resected invasive mucinous adenocarcinomas of the lung: related factors and comparison with resected nonmucinous adenocarcinomas
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2016.03.011
– volume: 6
  start-page: 244
  year: 2011
  ident: 10.1016/j.athoracsur.2020.09.042_bib1
  article-title: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e318206a221
– volume: 31
  start-page: 992
  year: 2013
  ident: 10.1016/j.athoracsur.2020.09.042_bib3
  article-title: New pathologic classification of lung cancer: relevance for clinical practice and clinical trials
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.46.9270
– volume: 117
  start-page: 4257
  year: 2011
  ident: 10.1016/j.athoracsur.2020.09.042_bib15
  article-title: Clinicopathological features of lung adenocarcinoma with KRAS mutations
  publication-title: Cancer
  doi: 10.1002/cncr.26010
– volume: 24
  start-page: 653
  year: 2011
  ident: 10.1016/j.athoracsur.2020.09.042_bib7
  article-title: Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2010.232
– volume: 37
  start-page: 211
  year: 2013
  ident: 10.1016/j.athoracsur.2020.09.042_bib4
  article-title: HNF4α as a marker for invasive mucinous adenocarcinoma of the lung
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0b013e31826be303
– volume: 8
  start-page: 52
  year: 2013
  ident: 10.1016/j.athoracsur.2020.09.042_bib13
  article-title: Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e3182769aa8
– volume: 44
  start-page: 2636
  year: 2013
  ident: 10.1016/j.athoracsur.2020.09.042_bib16
  article-title: Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2013.05.026
– volume: 23
  start-page: 3288
  year: 2005
  ident: 10.1016/j.athoracsur.2020.09.042_bib12
  article-title: Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.19.240
– volume: 10
  start-page: 1243
  year: 2015
  ident: 10.1016/j.athoracsur.2020.09.042_bib2
  article-title: The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0000000000000630
– volume: 10
  start-page: 1156
  year: 2015
  ident: 10.1016/j.athoracsur.2020.09.042_bib8
  article-title: Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0000000000000579
– volume: 123
  start-page: 1868
  year: 2003
  ident: 10.1016/j.athoracsur.2020.09.042_bib11
  article-title: Clinical characteristics of pneumonic-type adenocarcinoma of the lung
  publication-title: Chest
  doi: 10.1378/chest.123.6.1868
– volume: 38
  start-page: 1118
  year: 2014
  ident: 10.1016/j.athoracsur.2020.09.042_bib14
  article-title: Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000000246
SSID ssj0002155
Score 2.5040743
Snippet Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma. However, the clinical course and prognostic outcomes following IMA...
SourceID proquest
crossref
elsevier
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 1118
Title Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0003497520320014
https://dx.doi.org/10.1016/j.athoracsur.2020.09.042
https://www.proquest.com/docview/2465441089
Volume 112
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbK9sILAgFiMJCR9jYFJc6PxuJpTKCxsSKxTuwJy7EdLR1LUZsgjX-Ef5ezYzvpVETZS5Q4OrfOffl8vpzvENrLkkzkMi-DhHAZJEpFAU2JDKKcSl0caaxMyP_pJDs6T44v0ovR6Pcgaqltijfi19p9JXfRKrSBXvUu2f_QrO8UGuAc9AtH0DAcN9Lx4bCIIHDAoqOxz20Dv6aW--9sENbH-ic3YeqnrahMTlbtLp_M68A3fGq1ewRICOa2hW6zfD3r0dTnWm4uATiiEvvLwaZq49Zulq0JD5jyq_bGM_4Zv4JrU9FIfyiqwGr1RD-_4dfmxtll5YE6AYFae8e6rUNVw4feCRL5OLeecWNdxS5dYdyIDKCVDPgTmDcfzMV6f9Nanu9cDjN43GbAMFpY6pPQpKztsnWtpta-NeX5QEQX4zZjfU9M98RCyqCne2ibwPoDCHT74OTL1xM_yYOllLpijHp4NkisCx1c_6_-ZvncsgGMYTN9iB7YFQk-6OD1CI1U_Rh966GF5yV20MIOWthCCztoYYckDNDCQ2hhDS28Cq0n6PzD--nhUWBLcQQijfImyGRWKiJznsFZUmRCZAWXYWky_tFSJrGksRgTeO-VKLWNnIuS8LiIBZeURPFTtFXPa_UMYbCGYAJWMpWpShQpaFgqqmClXohQJ6ndQWP3mJiweep1uZTv7F_K2kGRl_zR5WrZQIY6TTC3FxlmTwZA20D2rZe19mpnh24o_dopngGl6-90vFagFkZ0jsMkCnP6_A4jeoHu9y_iLtpqFq16CYZzU7yyIP4DquvLaw
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+Surgical+Outcomes+Between+Invasive+Mucinous+and+Non-Mucinous+Lung+Adenocarcinoma&rft.jtitle=The+Annals+of+thoracic+surgery&rft.au=Matsui%2C+Takuya&rft.au=Sakakura%2C+Noriaki&rft.au=Koyama%2C+Shin&rft.au=Nakanishi%2C+Keita&rft.date=2021-10-01&rft.issn=0003-4975&rft.volume=112&rft.issue=4&rft.spage=1118&rft.epage=1126&rft_id=info:doi/10.1016%2Fj.athoracsur.2020.09.042&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_athoracsur_2020_09_042
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4975&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4975&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4975&client=summon